Table 1 Baseline characteristics and most reported adverse events in BCMA directed immunotherapy in patients with relapsed and/or refractory multiple myeloma.

Number of patients

584

477

723

Number of adverse events reported

2132

874

1363

Age- yrs. median (interquartile)

66 (58.5–71)

66 (57.8–71)

65 (57–72)

Female (%)^a

225 (38.5)

117 (24.5)

229 (31.8)

Death (%)^a

68 (11.6)

82 (17.2)

159 (22.1)

Life threatening (%)^a

43 (7.4)

42 (8.8)

81 (11.3)

Hospitalization (%)^a

208 (35.6)

226 (47.4)

385 (53.5)

CRS (%)^a

344 (16.1)

90 (10.3)

130 (9.5)

ICANS (%)^a

80 (3.8)

29 (3.3)

34 (2.5)

Non-ICANS neurotoxicity (%)^a

215 (10.1)

56 (6.4)

52 (3.8)

Pneumonia (%)^a

4 (0.2)

20 (2.3)

63 (4.6)

Sepsis (%)^a

15 (0.7)

17 (2.0)

46 (3.4)

COVID-19 infection (%)^a

4 (0.2)

24 (2.7)

69 (5.0)

Infection (%)^a

4 (0.2)

2 (0.2)

19 (1.4)